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   INTRODUCTION 
  Toxoplasma gondii   is a ubiquitous parasite whose defini-
tive hosts are members of the Felidae (cat family). Cats shed 
millions of environmentally resistant oocysts in their feces 
after primary infection and are usually without clinical mani-
festations of disease.  1–  4   Intermediate hosts include almost all 
warm-blooded mammals and birds, including humans, who 
accumulate infectious, quiescent stages (bradyzoites) of the 
parasite in their tissues, particularly in skeletal muscle and the 
brain.  5,  6   Intermediate hosts may acquire infection by consum-
ing raw or undercooked flesh from other intermediate hosts,  5  
or by ingesting oocysts from the environment.  7,  8  Environmental 
sources of   T. gondii   (oocysts) include soil, water, shellfish, 
fruits, and vegetables.  9–  16  
  Toxoplasma gondii   is of particular concern in humans 
because of the potential for transmitting the disease to the 
unborn fetus if the mother is infected for the first time dur-
ing pregnancy.  17,  18   Toxoplasmosis most commonly manifests as 
a mild, flu-like illness with low-grade fever, myalgia, malaise, 
and headache, but primary infection in humans may also cause 
spontaneous abortion, fetal mental and pyschomotor retarda-
tion, retinochoroiditis, encephalitis, and hepatitis.  6,  17,  18   Patients 
with a history of recent miscarriage, ocular infection, jaundice, 
hepatosplenomegaly, and cirrhosis of the liver may be referred 
into a testing protocol termed “TORCH” (  T. gondii  , other [if 
done, e.g., syphilis, varicella zoster virus, human immunode-
ficiency virus, and parvovirus B19], rubella, cytomegalovirus 
[CMV], and herpes simplex viruses [HSVs]), to rule out infec-
tions with similar clinical presentations. 
  The TORCH infections can cause serious illness or death to 
the fetus or neonate, so TORCH testing is important to pro-
tect the health of neonates that may have been exposed to one 
or more TORCH pathogens   in utero  . It is also important to 
identify the etiologic agent associated with clinical disease in 
symptomatic adults so that appropriate treatment can be initi-
ated. The classic triad of symptoms associated with congenitally 
acquired toxoplasmosis includes hydrocephaly, intracranial 
calcifications, and ocular lesions.  17   Rubella infection of the 
fetus causes birth defects and blindness, hearing loss, and men-
tal retardation.  19   Congenital CMV has similar manifestations 
to toxoplasmosis and rubella that include sensorineural hear-
ing loss, mental retardation, and retinochoroiditis.  20   Neonatal 
HSV (usually acquired during vaginal delivery) may lead to 
external infection of the skin, eyes, and mouth, central ner-
vous system (CNS) infection (encephalitis), or disseminated 
infection involving several organs such as the brain, liver, and 
lung.  21   Disseminated infection is a more frequent cause of 
mortality.  21   Most clinical disease in neonates is caused by HSV 
type 2 (HSV-2) infection.  21,  22  
  In Qatar, better prenatal care and greater vigilance with 
regard to TORCH infections may lead to earlier and more 
effective therapy. No specific   T. gondii   prevention program 
exists in Qatar other than routine prenatal counseling, which 
may or may not include advice about how to prevent toxo-
plasmosis. Increasing concern has been raised about toxoplas-
mosis because of the large, indigenous feral cat population in 
the capital city of Doha, where most of the inhabitants live. 
Doha and its surrounding communities had experienced prob-
lems controlling rodents for decades, so domestic cats were 
introduced in the 1960s to ameliorate the problem. The cat 
population is now estimated to exceed 2 million animals (Cat 
Control Unit, personal communication). Cats are rarely kept 
as pets in Qatar and the vast majority leads a feral existence 
on the streets, congregating near human dwellings, businesses, 
restaurants, and in the market places where food for human 
consumption is prepared and traded.  23   They survive by scav-
enging on garbage and preying on rodents, and some are sup-
plemented with food by the local residents. 
  This analysis updates and extends an earlier study of 
patients referred for TORCH testing in Qatar.  24   The  aims 
were to determine the prevalence of   T. gondii   in the subpopu-
lations of women of childbearing age and infants from among 
all patients referred for TORCH testing in Qatar, and to deter-
mine if specific TORCH pathogens (CMV, HSV-1, HSV-2, and 
rubella) were associated with   T. gondii   infection in patients 
referred for TORCH testing, after controlling for demographic 
  T. gondii   risk factors. 
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   MATERIALS AND  METHODS 
    Study location, selection of subjects, and inclusion criteria.  
  Doha, the capital city of Qatar, is located on the Arabian Gulf 
and encompasses about 285 km  2  . The city is populated by 
about 1 million residents, many of whom are immigrants from 
other Middle Eastern countries, Africa, and Asia. The climate 
of Qatar is arid, with sparse annual rainfall averaging only 0.1–
3.2 cm. 
  The entire patient population included persons who had 
symptoms compatible with those of TORCH pathogens (ocu-
lar disease, hepatosplenomegaly, cirrhosis), women with a his-
tory of miscarriage(s), and their most recent child, who was 
usually < 1 year of age. Testing was carried out in Qatari hospi-
tals and outpatient clinics between 2005 and 2008, and patients 
came from such specialties as maternity, pediatrics, internal 
medicine, and gastroenterology. Patient confidentiality was 
maintained throughout and the data set were de-identified so 
as to mask patient identity from the investigators. The study 
was approved by the Medical Research Center & Research 
Committee at Hamad Medical Cooperation, Qatar (research 
protocol no. 8036/08). 
   Blood collection and serological tests.   Each subject had 5 mL 
of whole blood collected by venipuncture in plain tubes. Blood 
samples were then transported to the virology laboratory 
at Hamad Medical Corporation according to hospital 
arrangements, centrifuged to remove blood cells, and stored 
at +4°C for 48 hours or frozen at −20°C for longer storage. 
Serologic tests for anti-  T. gondii   IgG and IgM antibodies were 
performed as previously described.  24   Commercially available 
enzyme immunoassay Enzygnost kits (Dade Behring GmbH, 
Marburg, Germany) were used to detect the presence of 
antibodies against   T. gondii  , rubella virus, and CMV, and the 
Novagnost EIA kits (NovaTec Immundiagnostica GmbH, 
Dietzenbach, Germany) for HSV-1/HSV-2. Sera with values 
of  < 10 IU/mL were defined as negative for rubella IgG 
antibodies and those with values ≥ 10 IU/mL as positive. 
The latter test has a published sensitivity (Se) of 100% and 
specificity (Sp) 98.5%. Rubella IgM testing was not included 
in this analysis because the testing protocol for rubella IgM 
included only patients with negative rubella IgG results and 
symptoms of fever and rash, which increases the likelihood of 
the patient being a clinical rubella case. For CMV, sera with 
values < 0.5 IU/mL were defined as negative, those between 
0.5 and 0.7 IU/mL as equivocal, and those > 0.7 IU/mL as 
positive. The reported Se and Sp of this test was 99.3% and 
98.2%, respectively. For CMV IgM, sera were considered 
negative if the ratio of the optical densities, OD  sample /OD cutoff , 
were < 90%, equivocal between 90% and 100% and positive 
if > 100%, and the manufacturer reported Se and Sp of 95% 
and 100%, respectively. In HSV-1 and HSV-2 Novagnost tests, 
sera were considered negative for HSV-1 or HSV-2 IgM or 
IgG antibodies if values were < 8.5 IU/mL, equivocal between 
8.5 and 11.5 IU/mL, and positive if > 11.5 IU/mL. Se and Sp, 
respectively, for each of the four tests were reported as follows: 
HSV-1 IgG and IgM > 95% and > 95%, HSV-2 IgG 87.5% and 
94.1%, and HSV-2 IgM > 95% and > 95%. The HSV-1 and 
HSV-2 immunoassays are considered to be semi-quantitative. 
   Definition  of  variables.     Age was classified into ranges by yr 
as previously described,  24   except that infants were classified 
into ages of ≤ 6 mo and 7– < 12 mo. In this analysis, the age group 
of 7–  < 12 mo was used as the referent group because about 
one-quarter of infants ≤ 6 mo of age had IgG antibodies against 
  T. gondii   in their sera that were most likely acquired   in utero . 
Maternally acquired antibodies usually disappear by 6 mo of 
age.  25   However, IgG antibodies in infant sera can also appear 
as a result of congenital infection.  26   For patients ≥ 12 mo of 
age, the categories in yr were 1– < 2, 2–10, 11–20, 21–29, 30–45, 
and > 45. Presence of IgM antibodies in infant sera suggests 
that toxoplasmosis was transmitted congenitally,  27,  28   but the 
tests lack sensitivity, missing 50–75% of incident cases.  27,  29,  30  
Prevalence of   T. gondii   antibodies in the female population 
was also assessed separately by age in yr to determine  T. gondii  
prevalence in females of childbearing age (15–45 yr). 
 Subjects in the study came from 55 countries that were grouped 
into the following geographic regions: Arabian Peninsula 
(Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, United 
Arab Emirates, and Yemen); Africa (Algeria, Egypt, Eritrea, 
Ethiopia, Ivory Coast, Kenya, Libya, Mauritania, Morocco, 
Senegal, Somalia, Sudan, and Tunisia); Asia (Afghanistan, 
Bangladesh, Iran, India, Indonesia, Macao, Malaysia, Nepal, 
North Korea, Pakistan, Philippines, Singapore, South Korea, 
Sri Lanka, and Vietnam); Eastern Mediterranean/Eastern 
Europe (Armenia, Bulgaria, Jordan, Lebanon, Palestine, 
Romania, Syria, and Turkey); American continent (Canada, 
Cuba, United States, and Venezuela); and Other/Unknown 
(Australia, France, New Zealand, Spain, Russia, Ukraine, and 
United Kingdom). Year of testing was included as a categor-
ical variable with 2005 as the referent year. Association of 
  T. gondii   seropositivity with TORCH pathogens included 
rubella (IgG) status, CMV IgG/IgM status, HSV-1 IgG/IgM 
status, and HSV-2 IgG/IgM status. 
   Statistical analyses.   Estimates for the incidence of congenital 
toxoplasmosis were determined using two methods: defining a 
case as an infant ≤ 6 mo of age with concurrent IgM and IgG 
  T. gondii   antibodies in serum; or a woman of childbearing age 
with IgM antibodies to   T. gondii   in her serum. Both methods 
used the total number of live births in Qatar between 2005 
and 2008 as the denominator for population size and assumed 
that all cases of congenital toxoplasmosis or incident cases 
of toxoplasmosis in pregnancy would have been detected. 
For the estimate based on women of childbearing age 
with   T. gondii   IgM antibodies, the probability of   T. gondii  
transmission to the fetus was assumed to be between 25% 
and 50%. The lower limit of the 95% confidence interval 
(CI) for the estimate based on 25% transmission probability 
and the upper limit of the 95% CI for the estimate based on 
50% transmission probability delimited the ranges for the 
estimates derived for IgM-positive women of childbearing age. 
Confidence intervals were calculated using Szklo and Nieto, 
Appendix A.  31  
  The binary logistic regression analyses were conducted in 
Minitab Release 14.2 (Minitab Inc., State College, PA). Each 
explanatory factor in turn was fitted alone (one-way analyses) 
with the dependent variable (presence/absence of antibod-
ies to   T. gondii  ) and then full factorial models were simpli-
fied by using stepwise backward elimination. Factors were 
then fitted in minimum sufficient models where   P   values 
were considered significant if ≤ 0.05. The Hosmer-Lemeshow 
test was used to verify model fit. The Cochran-Armitage test 
was used to evaluate a trend of increasing   T. gondii   IgG sero-
prevalence with age and for decreasing IgM seroprevalence 
from 2005 to 2008 using SAS version 9.2 (SAS Institute Inc., 
Cary, NC). 628 ABU-MADI AND OTHERS
    RESULTS 
  Of the 1,857 patients referred for TORCH testing in 
2005–2008, 4.1% percent (  N   = 3 missing data) and 30.8% of 
patients tested positive for IgM and IgG   T. gondii   antibodies, 
respectively (  Table 1  ).   Toxoplasma gondii   IgG and IgM sero-
prevalence by age group for residents of Qatar is depicted in 
 Figure 1 . Among 823 women of childbearing age (15–45 yr), 289 
(35.1%) had IgG antibodies and 43 (5.2%) had IgM antibodies 
against   T. gondii   ( N   = 1 of unknown IgM status).   Toxoplasma 
gondii  IgG seroprevalence increased with advancing age in both 
males and females, with a combined prevalence of 8% in 2 to 
10 years of age compared with 54% in patients over 45 years of 
age. The Cochran-Armitage trend test by age category showed 
a significant association with increasing age (Z-statistic 7.97, 
7 degrees of freedom [df],   P   < 0.01). This was markedly differ-
ent from the age prevalence of rubella virus and CMV. Rubella 
IgG seroprevalence ranged from 50% to 78% in all age groups 
from 1–  < 2 yr and up (  Table 1  ). In Qatar, vaccination against 
rubella has been mandatory for children before their first birth-
day since the 1970s. The CMV IgG seroprevalence was around 
80% at young ages (2 to 10 years of age) and generally > 90% 
in all age groups from 11–20 yr and up. In contrast, HSV-1 and 
HSV-2 IgG seroprevalence almost doubled in the age group 
encompassing teens (11–20 yr) compared with 2 to 10 years of 
age, and remained relatively stable thereafter. Notably, preva-
lence of HSV-1 IgG was higher than that of HSV-2 in adults 
(21 and up): 65–79% compared with 17–30%, respectively. 
       Of  the  353  infants  in  the  study  aged  ≤ 6 mo, 81 (22.9%) had 
detectable anti-  T. gondii   IgG antibodies that may be passively 
  Table  1 
    The number and percentage of high-risk patients testing positive for TORCH pathogens in Qatar by gender and age group, 2005–2008 *   
Age group
  Toxoplasma 
gondii   IgG n (%)
  T. gondii   IgM 
n (%)
Rubella IgG 
n (%)
CMV IgG 
n (%)
CMV IgM 
n (%)
HSV-1 IgG 
n (%)
HSV-1 IgM 
n (%)
HSV-2 IgG 
n (%)
HSV-2 IgM 
n (%)
Females
≤ 6 mo (  N   = 167) 41 (25) 3 (2) 104 (62) 157 (95) 9 (5) 86 (52) 0 (0) 51 (31) 0 (0)
7–11 mo (  N   = 22) 1 (5) 0 (0) 3 (14) 16 (73) 1 (5) 3 (14) 0 (0) 0 (0) 1 (5)
1–< 2 yr (  N   = 16) 1 (6) 1 (6) 8 (50) 10 (62) 1 (6) 3 (19) 0 (0) 1 (6) 0 (0)
2–10 yr (  N   = 38) 4 (11) 0 (0) 25 (66) 30 (79) 3 (8) 13 (34) 1 (3) 5 (13) 5 (13)
11–20 yr (  N   = 66) 9 (14) 2 (3) 42 (64) 60 (91) 2 (3) 40 (61) 1 (2) 14 (21) 6 (9)
21–29 yr (  N   = 367) 114 (31) 20 (5) 285 (78) 352 (96) 11 (3) 246 (67) 6 (2) 87 (24) 27 (7)
30–45 yr (  N   = 404) 167 (41) 21 (5) 300 (74) 394 (98) 10 (2) 301 (75) 2 (0.5) 122 (30) 33 (8)
> 45 yr (  N   = 76) 41 (54) 2 (3) 49 (64) 74 (97) 2 (3) 60 (79) 0 (0) 14 (18) 4 (5)
  Total   ( N   = 1,156) 378 (33) 49 (4) 816 (71) 1093 (95) 39 (3) 752 (65) 10 (1) 294 (25) 76 (7)
Males
≤ 6 mo (  N   = 186) 40 (22) 0 (0) 127 (68) 178 (96) 8 (4) 101 (54) 1 (1) 60 (32) 1 (1)
7–11 mo (  N   = 26) 1 (4) 0 (0) 2 (8) 17 (65) 1 (4) 5 (19) 0 (0) 3 (12) 1 (4)
1–< 2 yr (  N   = 19) 0 (0) 0 (0) 11 (58) 16 (84) 2 (11) 3 (16) 2 (11) 3 (16) 0 (0)
2–10 yr (  N   = 35) 2 (6) 1 (3) 18 (51) 28 (80) 1 (3) 10 (29) 0 (0) 3 (9) 1 (3)
11–20 yr (  N   = 35) 6 (17) 1 (3) 20 (57) 31 (89) 0 (0) 22 (63) 0 (0) 6 (17) 1 (3)
21–29 yr (  N   = 123) 37 (30) 7 (6) 84 (68) 116 (94) 6 (5) 81 (66) 2 (2) 32 (26) 7 (6)
30–45 yr (  N   = 163) 62 (38) 12 (7) 115 (71) 158 (97) 3 (2) 108 (66) 1 (0.6) 37 (23) 11 (7)
> 45 yr (  N   = 114) 46 (40) 6 (5) 74 (65) 111 (97) 5 (4) 75 (66) 0 (0) 19 (17) 7 (6)
  Total   ( N   = 701) 194 (28) 27 (4) 451 (64) 655 (93) 26 (4) 405 (58) 6 (1) 163 (23) 29 (4)
    *     CMV = cytomegalovirus; HSV = herpes simplex virius.   
  Figure   1.      Toxoplasma gondii   IgG and IgM seroprevalence by age category and gender in high-risk patients referred for TORCH testing in 
Qatar between 2005 and 2008. Exact binomial 95% confidence intervals (CIs) were computed using SAS software (SAS Institute Inc.) .    629 TORCH PATHOGENS IN HIGH-RISK PATIENTS FROM QATAR
transferred by the placenta, compared with only 3 (0.8%) with 
IgM antibodies (  Table 1  ). All three infants with IgM titers also 
tested positive for IgG antibodies and were most likely con-
genitally infected. Using cases as defined for infants and total 
live births of 13,401 in 2005, 14,120 in 2006, 15,681 in 2007, and 
17,210 in 2008, the annual incidence of congenital toxoplas-
mosis from 2005 to 2008 was estimated to be 0.5 cases (95% 
CI 0.1–1.5 cases) per 10,000 live births. If the number of cases 
was based on the detection of anti-  T. gondii   IgM antibodies 
in high-risk women of childbearing age with the parameters 
defined in the methods section, the estimated incidence of 
congenital toxoplasmosis between 2005 and 2008 ranged from 
0.9–5.5 cases per 10,000 live births. 
  In the one-way analyses, presence of   T. gondii   IgG antibod-
ies was positively associated with older age; African, Asian, or 
East Mediterranean/European nationality; positive CMV IgG 
status; positive HSV-1 IgG status; and positive HSV-2 IgM sta-
tus (  Table 2  ). It was negatively associated with male gender 
and rubella IgG seropositivity. In contrast, there was no asso-
ciation between   T. gondii   IgM status and age or nationality, 
but positive tests were associated with seropositivity to HSV-1 
IgG and HSV-2 IgM antibodies. In addition, the one-way anal-
ysis revealed a lower prevalence of positive   T. gondii   IgM 
results in 2008 compared with 2005 (  Table 2  ). A subsequent 
trend test indicated a decline in the prevalence of anti-  T. gon-
dii   IgM antibodies between 2005 and 2008 (Z-statistic 2.09, 
1 df,   P   = 0.037). 
      In  multifactorial  analyses  ( Table  3 ),  anti- T. gondii   IgG 
seropositivity was associated with older age (χ  2   78.43, 7 df, 
  P   < 0.001); African, East Mediterranean, or East European 
  Table  2 
    One-way analyses of factors associated with   Toxoplasma gondii   seropositivity in 1,857 TORCH-tested patients from Qatar, 2005–2008   
Risk factor IgM positive  *   (%) Odds ratio (95% confidence interval) IgG positive (%) Odds ratio (95% confidence interval)
Sex
Female 49 (4) 1.00 378 (33) 1.00
Male 27 (4) 0.91 (0.56–1.46) 194 (28)   0.79 (0.64–0.97)  ‡  
Age group < 0.01  † 
≤ 6 mo 3 (1) Undefined 80 (23)   6.85 (1.63–28.8)  §  
7–< 12 mo 0 (0) Referent 2 (4) 1.00
1–< 2 yr 1 (3) Undefined 1 (3) 0.68 (0.06–7.77)
2–10 yr 1 (1) Undefined 6 (8) 2.06 (0.40–10.7)
11–20 yr 3 (3) Undefined 15 (15)   4.01 (0.88–18.3)  ¶  
21–29 yr 27 (6) Undefined 151 (31)   10.2 (2.45–42.8)  §  
30–45 yr 33 (6) Undefined 229 (40)   15.6 (3.75–64.8)  §  
> 45 yr 8 (4) Undefined 87 (46)   19.4 (4.58–82.3)  §  
Nationality ||  0.42 †  < 0.01  † 
Arabian Peninsula 28 (4) 1.00 168 (24) 1.00
African 15 (5) 1.27 (0.67–2.41) 129 (42)   2.39 (1.79–3.17)  §  
American continent 0 (0) Undefined 6 (32) 1.50 (0.56–4.01)
Asian 19 (3) 0.80 (0.44–1.45) 182 (30)   1.41 (1.10–1.80)  §  
East Medi-terranean/East European 13 (7) 1.73 (0.88–3.41) 79 (40)   2.16 (1.55–3.02)  §  
Other/unknown 1 (6) 1.53 (0.20–12.0) 8 (47)   2.89 (1.10–7.62)  ‡  
Year  tested 0.23 †  0.75 † 
2005 27 (5) 1.00 160 (32) 1.00
2006 17 (4) 0.78 (0.42–1.45) 119 (30) 0.91 (0.68–1.21)
2007 19 (4) 0.69 (0.38–1.26) 157 (32) 0.97 (0.74–1.26)
2008 13 (3)   0.50 (0.25–0.98)  ‡  136  (29) 0.87  (0.66–1.14)
CMV-IgG seropositivity
No 4 (4) 1.00 15 (14) 1.00
Yes 72 (4) 1.12 (0.40–3.12) 557 (32)   2.90 (1.67–5.05)  §  
  N   = 1 missing data
CMV-IgM seropositivity
No 76 (4) 1.00 550 (31) 1.00
Yes 0 (0) Undefined 22 (34) 1.15 (0.68–1.95)
  N   = 1 missing data
Rubella IgG seropositivity
No 27 (5) 1.00 199 (34) 1.00
Yes 49 (4) 0.84 (0.52–1.36) 373 (29)   0.82 (0.67–1.01)  ¶  
HSV-1 IgG seropositivity
No 20 (3) 1.00 177 (25) 1.00
Yes 56 (5)   1.73 (1.03–2.90)  ‡  395  (34)  1.53 (1.24–1.89)  §  
HSV-1 IgM seropositivity
No 76 (4) 1.00 566 (31) 1.00
Yes 0 (0) Undefined 6 (38) 1.35 (0.49–3.74)
HSV-2 IgG seropositivity
No 62 (4) 1.00 433 (31) 1.00
Yes 14 (3) 0.68 (0.38–1.23) 139 (30) 0.98 (0.78–1.23)
HSV-2 IgM seropositivity
No 65 (4) 1.00 527 (30) 1.00
Yes 11 (11)   3.03 (1.55–5.94)  §  45  (43)  1.74 (1.17–2.60)  §  
    *     Three patients missing IgM results were excluded.   
  †   Global   P   value.  
  ‡     P   < 0.05   
  §     P   < 0.01   
  ¶   0.05  <   P   < 0.10   
  ||   Defined  in  Materials  and  Methods.  630 ABU-MADI AND OTHERS
nationality (χ  2  42.92, 5 df,  P  < 0.001); positive tests for CMV IgG 
(Z-statistic 1.93, 1 df,   P   = 0.054), and HSV-1 IgG (Z-statistic 
2.40, 1 df,   P   = 0.016); and negative rubella IgG serostatus 
(Z-statistic −4.53, 1 df,   P   < 0.001). No interactions were signifi-
cant, and neither gender nor the HSV-2 IgM response came 
into the equation. Anti-  T. gondii   IgM seropositivity was neg-
atively associated with year of testing (lower in 2008 versus 
2005) and positively associated with the presence of HSV-2 
IgG antibodies (  Table 4  ). The positive association with the 
HSV-1 IgG detected in the one-way analyses was not con-
firmed by the multifactorial analysis. 
             DISCUSSION 
  The results of TORCH testing suggest that approximately 
65% of women of childbearing age in Qatar have no IgG anti-
bodies to   T. gondii   (35.1% were IgG positive) and hence are 
susceptible to infection with toxoplasmosis. Pregnant women 
should take appropriate precautions to protect themselves 
against infection. Such precautions include cooking meat, espe-
cially lamb and pork, until it is well done; thorough washing 
of cutting boards used to prepare meat; wearing gloves when 
gardening; rigorous hand washing after handling raw meat 
or working in the soil; and avoiding contact with cat feces.  32  
Pregnant women who must clean out cat litter boxes should 
wear disposable gloves and collect feces daily, because it takes 
about 24 hr for oocysts to sporulate and become infectious at 
room temperature.  33   Forty-three women of childbearing age 
(5.2%) tested positive for anti-  T. gondii   IgM antibody. If they 
were pregnant, IgG avidity testing is the preferred method to 
confirm recent infection,  34   because IgM antibodies can per-
sist for months after initial infection in some individuals.  35,  36  
Alternate testing algorithms use higher IgM serologic titers as 
good indicators of acute infection when economic consider-
ations preempt additional tests.  37,  38  
  The presence of IgM antibody in three infants ≤ 6 mo of age 
suggested that they were congenitally infected. However, IgM 
testing reportedly fails to detect 50–75% of infected infants; 
therefore, 6–12 cases of congenital toxoplasmosis may have 
occurred between 2005 and 2008.  29,  30,  39   The results of IgM 
testing in women of childbearing age with high-risk pregnan-
cies (history of miscarriage) support this hypothesis, because 
43 cases of toxoplasmosis acquired during pregnancy would 
be expected to result in 11–21 cases of congenital toxoplas-
mosis, assuming a 25–50% probability of transmission to the 
fetus   in utero  . In north Jordan, women with a history of 3 to 
7 miscarriages were twice as likely to test seropositive for 
  T. gondii   as women with normal pregnancies.  40   Women  with-
out high-risk pregnancies are also at risk for acquiring toxoplas-
mosis and transmitting it to their fetus, but we do not know if 
the risk is similar to or differs from that of women with high-risk 
pregnancies in Qatar. Our estimates for the incidence of congen-
ital toxoplasmosis in Qatar are therefore speculative and should 
be confirmed by population-based studies. In the absence of 
universal screening, primary prevention of congenital toxoplas-
mosis through heightened maternal education efforts can be an 
effective strategy to prevent transmission to the fetus.  41,  42   
 The  overall   T. gondii   IgG seroprevalence (33%) during 
the time period (  Table 1  ) was similar to cross-sectional stud-
ies from Bahrain (28%),  43   Saudi Arabia (32%, 25%, 36%, and 
29% reported in 1991, 2001, 2002, and 2006, respectively),  44–  47  
and the United Arab Emirates (34%),  48   but much lower than 
that reported in two studies from Kuwait (96% and 58%) in 
the 1980s.  49,  50   Overall, prevalence of   T. gondii   IgM antibodies 
(4%) was also similar to countries in the Arabian Peninsula, 
e.g., Saudi Arabia (5% and 5.6% in the eastern region and 
Makkah, respectively),  45,  47   and the United Arab Emirates 
(3%).  48   Comparisons between the present and earlier studies 
should be made with caution, because different tests were used 
and most of the studies were conducted in specific subpopula-
tions, such as pregnant women or women of childbearing age. 
  Toxoplasma gondii   IgM prevalence in high-risk patients 
declined significantly between 2005 and 2008, but this was 
not the case for IgG seroprevalence. The latter is a measure 
of individuals infected months or years earlier; therefore, it is 
unlikely we would detect a decline until incidence decreases 
significantly for 5 to 10 years. Declining IgM seroprevalence 
suggests that knowledge about how to prevent   T. gondii   infec-
tion may have improved, the prevalence of   T. gondii   cysts in 
food animals in the region is declining, or that the feral cat 
control program is reducing the quantity of oocysts entering 
the environment. According to the Ministry of Public Health, 
  Table  4 
    Multifactorial analysis of factors  *   associated with IgM   Toxoplasma 
gondii   seropositivity in 1,854 TORCH-tested patients from Qatar, 
2005–2008  
Risk factor
Parameter 
estimate S.E.
Odds ratio (95% 
confidence interval)   P   value
Intercept −2.5587 0.2261 –
Year tested 0.04  † 
2005 1.00
2006 −0.3072 0.3190 0.74 (0.39–1.37) 0.34
2007 −0.6420 0.3229 0.53 (0.28–0.99) 0.05
2008 −0.9570 0.3578 0.38 (0.19–0.77) 0.01
HSV-2 IgG+ −0.7200 0.3228 0.49 (0.26–0.92) 0.03
    *     The table includes only those factors that retained significance after backward selection 
of the full factorial model.   
  †   Global   P   value.  
  Table  3 
    Multifactorial analysis of factors  *   associated with IgG   Toxoplasma 
gondii   seropositivity in 1,857 TORCH-tested patients from Qatar, 
2005–2008  
Risk factor
Parameter 
estimate S.E.
Odds ratio (95% 
confidence interval)   P   value
Intercept −3.9646 0.7671 –
Age group < 0.01  † 
≤ 6 mo 2.0297 0.7427 8.13 (1.90–4.9) 0.01
7–< 12 mo 1.00
1–< 2 yr −0.2952 1.2517 0.74 (0.06–8.65) 0.81
2–10 yr 0.7459 0.7367 2.38 (0.45–12.5) 0.31
11–20 yr 1.4148 0.6641 4.62 (0.99–21.5) 0.05
21–29 yr 2.3200 0.6109 11.40 (2.67–48.6) < 0.01
30–45 yr 2.6904 0.6097 16.50 (3.88–70.2) < 0.01
> 45 yr 2.9312 0.6212 21.02 (4.85–91.1) < 0.01
Nationality < 0.01  † 
Arabian Peninsula 1.00
African 0.8341 0.1532 2.30 (1.71–3.11) < 0.01
Asian 0.2512 0.1317 1.29 (0.99–1.66) 0.06
American Continent 0.1031 0.5270 1.11 (0.39–3.11) 0.85
East Mediterranean/
East European 0.8347 0.1794 2.28 (1.60–3.24) < 0.01
Other/unknown 0.9355 0.5181 2.55 (0.92–7.04) 0.07
CMV IgG+ 0.5862 0.3020 1.94 (0.99–3.25) 0.05
HSV-1 IgG+ 0.2983 0.1205 1.35 (1.06–1.71) 0.01
Rubella IgG+ −0.5261 0.1205 0.59 (0.47–0.75) < 0.01
    *     The table includes only those factors that retained significance after backward selection 
of the full factorial model.   
  †   Global   P   value.  631 TORCH PATHOGENS IN HIGH-RISK PATIENTS FROM QATAR
there have been no changes in public education programs with 
regard to   T. gondii  . The prevalence of   T. gondii   in meat, most 
likely sheep and goats, imported into Qatar for human con-
sumption is unknown. Reports from other countries in the 
region since 2001 found   T. gondii   prevalence of 23% to 52% 
in sheep,  46,  51–  56   suggesting that lamb, if it is undercooked (a 
prevalent cultural practice in this area), could be a source of 
  T. gondii   infection. Since the feral cat control program began 
in 2006, 9,637 cats have been spayed or neutered and 282 cats 
of 871 tested (32.3%) were serologically positive for   T. gondii  
antibodies. It seems likely that the cat control program may be 
reducing environmental exposure to   T. gondii   oocysts by con-
trolling reproduction and lessening the number of susceptible 
kittens entering the population, but testing of residents living 
within and outside trapping areas would be required to verify 
this hypothesis. 
  Multifactorial analysis found that the presence of   T. gondii  
IgG antibodies was positively related to age, African or East 
Mediterranean/East European nationality, and the presence of 
CMV IgG and HSV-1 IgG antibodies, whereas it was negatively 
associated with rubella IgG seropositivity. Increasing   T. gondii  
seroprevalence with age has been well documented, suggest-
ing that exposure is constant over the life span.  24,  57,  58   Persons 
originating from African nations, the East Mediterranean, and 
Eastern Europe were 2.3 times more likely to have   T. gon-
dii   IgG antibodies than persons who came from countries in 
the Arabian Peninsula. The increased risk may reflect cultural 
differences in eating practices, such as consumption of rare 
or undercooked meat and choice of meat, and weather pat-
terns that promote oocyst survival. Uduman and others  48   also 
found that   T. gondii   seroprevalence in Mediterranean Arabs 
was about twice as high as that of persons from the Arabian 
Gulf countries or the United Arab Emirates. Consumption of 
rare lamb or goat is common in the Eastern Mediterranean, 
Turkey, and Iran.  41,  59,  60   Extremely high temperatures and pro-
longed periods without rainfall in the Arabian Peninsula may 
inactivate oocysts in the environment rapidly, thereby reducing 
transmission to humans directly by soil contact or indirectly by 
food animals such as sheep and goats. For example, oocysts can 
survive 32 d at 35°C but only 9 d at 40°C.  33   Minimum and max-
imum temperatures in Qatar range from 25 to 45°C, respec-
tively, from June to September and rarely dip below 10°C in 
the winter months, and it is unclear how long oocysts might 
survive in this desert climate. In Costa Rica, oocysts in soil 
survived for up to 1 yr even when air temperatures reached 
30°C.  61   Studies of oocyst survival in the native Qatari climate 
would help to determine if oocysts represent a health hazard 
to persons with soil contact or if specific seasons of the year 
pose a greater hazard to humans and animals for acquiring 
  T. gondii   from the environment. 
  Three other TORCH pathogens were associated with 
  T. gondii   IgG seropositivity in the present analysis. Adjusting 
for age and nationality,   T. gondii-  seropositive patients were 
1.94 and 1.35 times more likely than seronegative patients 
to have previous exposure to CMV and HSV-1, respectively 
(  Table 3  ). They were about half as likely as seronegative 
patients to have IgG antibodies to rubella virus (odds ratio 
[OR] = 0.59). The CMV is transmitted directly from person 
to person, particularly between children, in saliva, urine, and 
genital secretions.  62   Most of the children and adolescents in 
Qatar appear to have been exposed to CMV with seropreva-
lences of 79% in the 2–10-year and 91% in the 11–20-year age 
groups. Poor socioeconomic conditions that are characterized 
by overcrowding and a lack of hand hygiene, and placing chil-
dren in daycare facilities, promote CMV transmission.  63   Low 
socioeconomic status is also associated with   T. gondii   infec-
tion,  57,  64–  66   which may explain why persons with positive CMV 
serostatus were more likely to be seropositive for   T. gondii  
IgG antibodies. The HSV-1 is an alpha-herpes virus that pro-
duces orolabial blisters or lesions. It remains latent for the life 
of the infected host and causes intermittent viral shedding, at 
which time it is infectious to susceptible persons. In the past, 
most primary HSV-1 infections were oral, and were acquired 
in childhood by direct mucosal or cutaneo-mucosal contact 
with an infected person.  67   Improved hand hygiene in devel-
oped countries has reduced the incidence of oral HSV-1 in 
childhood, whereas primary genital HSV-1 (acquired during 
sexual contact) has become more common in the teen years 
and young adulthood.  68–  71   In Israel, genital HSV-1 has become 
more prevalent than HSV-2.  71   The association of HSV-1 IgG 
antibodies with   T. gondii   IgG seropositivity may be related 
to poor socioeconomic conditions during childhood, because 
HSV-1 IgG was highly prevalent in the 2–10-year (34%) and 
11–20-year (61%) age groups. Much like the association with 
CMV, an association between HSV-1 and socioeconomic fac-
tors has been documented in other countries.  69,  72,  73  
  Unfortunately, vaccines for CMV and HSV-1 have not yet 
been developed, but a vaccine against rubella virus has been 
available since 1969.  74   Most nations in the Middle East, includ-
ing Qatar, have rubella in their national immunization sched-
ules, whereas almost all nations in Africa do not.  75   Because the 
rubella virus IgG antibody test does not discriminate between 
vaccine-induced and naturally acquired immunity, seropositiv-
ity to rubella IgG is likely to be a surrogate for vaccine status. 
The reverse association for rubella virus with   T. gondii   IgG 
seropositivity is probably related to higher socioeconomic sta-
tus, which entails better access to health care, more hygienic 
living conditions, and less occupational contact with soil. 
Soil contact, either by occupational exposure or gardening, 
is a well-recognized risk for   T. gondii   seropositivity in many 
nations.  41,  57,  76–  79   It would have been desirable to obtain infor-
mation about soil exposure and other factors known to be 
associated with   T. gondii   seropositivity, such as cat contact and 
consumption of undercooked meat, from patients referred for 
TORCH testing, but these data were not collected. Such data 
could help determine the extent to which environmental expo-
sure to oocysts and/or exposure by the food chain contribute 
to human toxoplasmosis in Qatar, so that appropriate preven-
tive measures can be adopted. 
  Only limited conclusions can be drawn about the preva-
lence of   T. gondii   in Qatar from this study, because it focused 
on a specific, high-risk population. If patients included in the 
study were more likely to be infected with toxoplasmosis, we 
would then overestimate the prevalence of   T. gondii   in Qatar. 
Conversely, if we failed to detect asymptomatic cases, which 
are more likely, the burden of toxoplasmosis may be underesti-
mated. Nonetheless, the proportion of previously infected per-
sons was similar to other countries in the Arabian Peninsula. 
The high percentage of at-risk females in their childbearing 
years (65%) suggests that pregnant women should receive coun-
seling during their antenatal visits on how to prevent   T. gon-
dii   infection. Population-based studies or universal screening 
of newborns over a specified time period could elucidate the 
true burden of congenital toxoplasmosis in Qatar and suggest 632 ABU-MADI AND OTHERS
priorities for public health action. Future studies would ben-
efit from questions that assess exposure to previously identi-
fied risk factors for   T. gondii   infection, such as recreational or 
occupational exposure to soil, drinking water source, contact 
with domestic pets and food animals, and practices related to 
cooking and preparing meat. 
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